AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older

뉴스 본문을 불러오고 있어요.

AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older | 웨이프 WAPE

AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older

기사 요약

관련 종목

댓글 —